Ipilimumab

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.

Ipilimumab is indicated in the following cancerous conditions: Melanoma Renal Cell Carcinoma (RCC) Colorectal Cancer Hepatocellular Carcinoma Non-Small Cell Lung Cancer (NSCLC) Malignant Pleural Mesothelioma Esophageal Cancer - Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

• Cutaneous Melanoma
• Hepatocellular Carcinoma
• Metastatic Esophageal Squamous Cell Carcinoma
• Metastatic Melanoma
• Metastatic Non-Small Cell Lung Cancer
• Microsatellite Instability High Metastatic Colorectal Cancer (CRC)
• Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC)
• Recurrent Non-small Cell Lung Cancer
• Unresectable Melanoma
• Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC)
• Unresectable Malignant Pleural Mesothelioma (MPM)
• Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)